Regenxbio initiated with a Buy at Goldman Sachs

Goldman Sachs initiated coverage of Regenxbio with a Buy rating and $38 price target. The company is building and improving on the AAV-based approach to expand addressable patient populations, the analyst tells investors in a research note. The firm sees the potential for Regenxbio’s gene therapy platform to address unmet needs in multiple attractive markets including in ophthalmology, Duchenne muscular dystrophy and Hunter syndrome. Goldman sees a “tangible catalyst path” driving Regenxbio share performance over the near to intermediate term.